Active, Not Recruiting
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients - CA209-143
Mis à jour: 12 octobre, 2023 | ClinicalTrials.gov
Phase
Sexe(s)
Tranche d’âge
Active, Not Recruiting
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Participants with histologically confirmed Grade IV malignant glioma - Previous treatment with radiotherapy and temozolomide (Cohorts 1, 1b and 2 only) - First recurrence of GBM (Cohorts 1, 1b and 2 only) - First diagnosis of GBM with resectable disease (Cohorts 1c Part A only) - First diagnosis of unmethylated MGMT GBM (Cohort 1d and Cohort 1c Part B only) - Karnofsky performance score of 70 or higher Exclusion Criteria: - More than 1 recurrence of GBM (Cohorts 1, 1b and 2 only) - Any recurrence of GBM (Cohorts 1c and 1d only) - Presence of extracranial metastatic or leptomeningeal disease - Active, known or suspected autoimmune disease - Clinically significant cardiovascular disease - Prior bevacizumab or other Vascular Endothelial Growth Factor (VEGF) or anti-angiogenic treatment (Cohort 2 only)
Nous vous recommandons fortement de contacter BMS pour signaler les effets secondaires (événements indésirables).
Les effets secondaires (événements indésirables) et les autres événements à signaler sont définis ici.
Signaler des effets secondaires (effets indésirables) ou des plaintes concernant la qualité du produit: Informations médicales
